Calls for prescription drug reform blast the original biotech blue-chip stock in September. Could Amgen have more downside to come, or is this latest dip an early holiday gift?
Owners of the set-top box spend far more time with authenticated apps than users of rival products.
Amgen and Allergan's ABP 215 biosimilar to Avastin posted positive results in phase 3 trials.
Jim Keller, the chief architect of AMD’s Zen, just left the company.
Atmel has underperformed the market over the past four years, but that underperformance will be over soon.
The new tablet was expected, but some of its features, add-ons, and the audience it was targeted at was not.
Expect these dividend-paying companies to boost their payouts soon.
As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
As we look to Apple's imminent product launch window, the company powering what many expect to be this year's marquee new feature could see its business take off.
New iMacs are said to be incoming with some solid enhancements over prior generation models.